amlodipine has been researched along with Cardiac Remodeling, Ventricular in 18 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia." | 9.13 | Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 7.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| "We sought to determine whether reperfusion and the calcium channel blocker amlodipine or the angiotensin-converting enzyme inhibitor enalapril, during healing over six weeks after myocardial infarction (MI), limit structural vascular remodeling in the noninfarct zone (NIZ)." | 7.71 | Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. ( Idikio, H; Jugdutt, BI; Kumar, D; Menon, V, 2002) |
| "To compare the effects of the calcium channel blocker amlodipine versus the angiotensin-converting enzyme inhibitor enalapril with or without reperfusion on infarct collagen and remodelling during healing after anterior myocardial infarction (MI)." | 7.70 | Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction. ( Jugdutt, BI; Musat-Marcu, S, 2000) |
| "Azelnidipine has beneficial effects on LV mass regression, transmitral flow, tissue Doppler, and LV longitudinal strain that are comparable to those of amlodipine on the same parameters." | 6.79 | Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. ( Ikeda, U; Izawa, A; Koyama, J; Miyashita, Y; Motoki, H; Takahashi, M; Tomita, T, 2014) |
| "A total of 33,357 patients (aged ≥ 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor were randomized to chlorthalidone, amlodipine, or lisinopril." | 5.24 | Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. ( Bang, CN; Davis, BR; Devereux, RB; Okin, PM; Simpson, LM; Soliman, EZ, 2017) |
| "The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA) showed that an amlodipine-based regimen prevented more cardiovascular events than an atenolol-based regimen in patients at high risk of hypertension." | 5.15 | Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension. ( Peuhkurinen, K; Peuhkurinen, S; Risteli, J; Uusimaa, P; Vuolteenaho, O; Ylitalo, A, 2011) |
| "Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia." | 5.13 | Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008) |
| "Although amlodipine, a long-acting L-type calcium channel blocker, reportedly prevents left ventricular remodeling and dysfunction after myocardial infarction, the mechanism responsible is not yet well understood." | 3.74 | Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. ( Aoyama, T; Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kawasaki, M; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Ushikoshi, H, 2007) |
| "Azelnidipine suppressed cardiac hypertrophy, fibrosis, NADPH oxidase and superoxide in spSHRs more potently than amlodipine, and was associated with lower heart rates than amlodipine." | 3.73 | Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. ( Ito, T; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Ogawa, H; Tanaka, T; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2006) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 3.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| "We sought to determine whether reperfusion and the calcium channel blocker amlodipine or the angiotensin-converting enzyme inhibitor enalapril, during healing over six weeks after myocardial infarction (MI), limit structural vascular remodeling in the noninfarct zone (NIZ)." | 3.71 | Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. ( Idikio, H; Jugdutt, BI; Kumar, D; Menon, V, 2002) |
| "We measured detailed left ventricular remodeling parameters in vivo (echocardiograms) repeatedly over 6 weeks and ex vivo (planimetry) at 6 weeks after myocardial infarction in 36 dogs randomized (factorial design) after reperfused or nonreperfused myocardial infarction to 6 weeks of twice daily oral therapy with the calcium channel blocker amlodipine (5 mg), the angiotensin-converting enzyme inhibitor enalapril (5 mg) or placebo, and 18 matching sham or control animals." | 3.71 | Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters. ( Jugdutt, BI; Menon, V, 2002) |
| "To compare the effects of the calcium channel blocker amlodipine versus the angiotensin-converting enzyme inhibitor enalapril with or without reperfusion on infarct collagen and remodelling during healing after anterior myocardial infarction (MI)." | 3.70 | Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction. ( Jugdutt, BI; Musat-Marcu, S, 2000) |
| "Valsartan has a beneficial effect on LV deformation and function presented in GLS." | 2.94 | Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography. ( Khairat, I; Khedr, L; Werida, R, 2020) |
| "Azelnidipine has beneficial effects on LV mass regression, transmitral flow, tissue Doppler, and LV longitudinal strain that are comparable to those of amlodipine on the same parameters." | 2.79 | Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. ( Ikeda, U; Izawa, A; Koyama, J; Miyashita, Y; Motoki, H; Takahashi, M; Tomita, T, 2014) |
| "Treatment with Amlodipine alone or combination with atorvastatin significantly decreased blood pressure, left ventricle mass index in SHR rats (P < 0." | 1.43 | Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats. ( Cui, W; Du, H; Hao, J; Li, Y; Lu, J; Xiao, B; Yang, X, 2016) |
| " We have now compared the effects of the ARB valsartan combined with cilnidipine or amlodipine on cardiac pathophysiology in DS rats." | 1.42 | Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. ( Harada, E; Hattori, T; Matsuura, N; Murohara, T; Nagasawa, K; Nagata, K; Niinuma, K; Takahashi, K; Takatsu, M; Watanabe, S, 2015) |
| "Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)." | 1.38 | Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Naseratun, N | 1 |
| Kobara, M | 1 |
| Watanabe, Y | 1 |
| Toba, H | 1 |
| Nakata, T | 1 |
| Khairat, I | 1 |
| Khedr, L | 1 |
| Werida, R | 1 |
| Bang, CN | 1 |
| Soliman, EZ | 1 |
| Simpson, LM | 1 |
| Davis, BR | 1 |
| Devereux, RB | 1 |
| Okin, PM | 1 |
| Motoki, H | 1 |
| Koyama, J | 1 |
| Izawa, A | 1 |
| Tomita, T | 1 |
| Miyashita, Y | 1 |
| Takahashi, M | 1 |
| Ikeda, U | 1 |
| Nagasawa, K | 1 |
| Takahashi, K | 1 |
| Matsuura, N | 1 |
| Takatsu, M | 1 |
| Hattori, T | 1 |
| Watanabe, S | 2 |
| Harada, E | 1 |
| Niinuma, K | 1 |
| Murohara, T | 1 |
| Nagata, K | 1 |
| Lu, J | 1 |
| Hao, J | 1 |
| Du, H | 1 |
| Xiao, B | 1 |
| Li, Y | 1 |
| Yang, X | 1 |
| Cui, W | 1 |
| Uusimaa, P | 1 |
| Peuhkurinen, S | 1 |
| Ylitalo, A | 1 |
| Vuolteenaho, O | 1 |
| Risteli, J | 1 |
| Peuhkurinen, K | 1 |
| Nagashima, A | 1 |
| Watanabe, R | 1 |
| Ogawa, M | 1 |
| Suzuki, J | 1 |
| Masumura, M | 1 |
| Hishikari, K | 1 |
| Shimizu, T | 1 |
| Takayama, K | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| Yu, GL | 1 |
| Liang, XQ | 1 |
| Zheng, JQ | 1 |
| Yamamoto, E | 1 |
| Lai, ZF | 1 |
| Yamashita, T | 1 |
| Tanaka, T | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Ito, T | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Ogino, A | 1 |
| Takemura, G | 1 |
| Kanamori, H | 1 |
| Okada, H | 1 |
| Maruyama, R | 1 |
| Miyata, S | 1 |
| Esaki, M | 1 |
| Nakagawa, M | 1 |
| Aoyama, T | 1 |
| Ushikoshi, H | 1 |
| Kawasaki, M | 1 |
| Minatoguchi, S | 1 |
| Fujiwara, T | 1 |
| Fujiwara, H | 1 |
| Ge, CJ | 1 |
| Lu, SZ | 1 |
| Chen, YD | 1 |
| Wu, XF | 1 |
| Hu, SJ | 1 |
| Ji, Y | 1 |
| Kumamoto, H | 1 |
| Okamoto, H | 1 |
| Watanabe, M | 1 |
| Onozuka, H | 1 |
| Yoneya, K | 1 |
| Nakagawa, I | 1 |
| Chiba, S | 1 |
| Mikami, T | 1 |
| Abe, K | 1 |
| Kitabatake, A | 1 |
| Jugdutt, BI | 3 |
| Musat-Marcu, S | 1 |
| Sandmann, S | 1 |
| Claas, R | 1 |
| Cleutjens, JP | 1 |
| Daemen, MJ | 1 |
| Unger, T | 1 |
| Nishikawa, N | 1 |
| Masuyama, T | 1 |
| Yamamoto, K | 1 |
| Sakata, Y | 1 |
| Mano, T | 1 |
| Miwa, T | 1 |
| Sugawara, M | 1 |
| Hori, M | 1 |
| Menon, V | 2 |
| Kumar, D | 1 |
| Idikio, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for amlodipine and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography.
Topics: Adipokines; Adiponectin; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2020 |
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Disease P | 2017 |
Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Azetidinecarboxylic Acid; Calcium Channel Blockers; D | 2014 |
Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Biomarkers; Collagen; Coll | 2011 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Sy | 2008 |
13 other studies available for amlodipine and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Chan | 2020 |
Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Dihydropyridines; Drug Evaluation, Preclinical; Drug T | 2015 |
Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blotting, West | 2016 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben | 2012 |
[Contrast of losartan, fosinopril and amlodipine on cardiomyocyte apoptosis and left ventricular remolding in hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Cardiotonic Agents; Female; Fosinopril; Hyp | 2001 |
Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Cardiomegaly; Dihydropyridines; Endomyocardial Fibros | 2006 |
Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling.
Topics: Amlodipine; Animals; Apoptosis; bcl-Associated Death Protein; Calcineurin; Calcineurin Inhibitors; C | 2007 |
Beneficial effect of myocardial angiogenesis on cardiac remodeling process by amlodipine and MCI-154.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Capillaries; Cardiomyopathy, Dilated; Cardiotonic Age | 1999 |
Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction.
Topics: Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel | 2000 |
Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Heart Failure; Hemodynamics; Hypertrophy, Left Ventri | 2001 |
Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats.
Topics: Amlodipine; Analysis of Variance; Animals; Antihypertensive Agents; Calcium Channel Blockers; Collag | 2001 |
Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Calcium Channel Blockers; | 2002 |
Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Cardiac Vol | 2002 |